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Older patients suffer from a greater number of medical morbidities, consume a greater 
number of prescribed medications, and report lower levels of quality of life than their 
younger counterparts.  The objectives of this study were to determine whether there is 1) 
an association between medical morbidity and symptom burden or 2) an association 
between medication use and symptom burden.  This was a cross-sectional study of the 
symptoms, medical morbidities, and medications reported by 159 community-dwelling 
male patients 65 years of age or older.  Correlations were drawn using linear regression 
analysis.  On average, the participants in this study suffered from 2.56 +/- 1.36 medical 
morbidities, were prescribed 7.91+/- 2.83 medications, and reported 3.17 symptoms at 
any severity.  The results of this study demonstrated a direct correlation between number 
of medical morbidities and symptom burden (R2 = 0.94).  Our study did not find a 
significant correlation between medication use and symptom burden (R2 = 0.20).  The 
findings of this study suggest that the number of medical morbidities has a stronger 
negative impact on symptom burden than the number of medications used.  Thus, when 
attempting to improve quality of life for older patients, physicians should focus on the 
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It is worthwhile to secure the happiness of the patient as well as to prolong his life. 
-- Dr. William J. Mayo, 1935 
 
This quote highlights the responsibility of health care providers to offer medical 
services not only to prolong life, but also to improve the quality of life for their patients.  
The growth of sophisticated life-sustaining medical technology in the last century, 
combined with a greater focus on medical care at the end of life, has contributed to a 
longer life for many people in the United States.  Whereas only one in 25 Americans 
reached age 65 in 1900, one in every eight Americans was at least 65 years old in 1990.  
This dramatic increase in life expectancy has been shown to be largely the result of a 
decline in mortality among middle-aged and elderly populations.  For example, in 1900, a 
person aged 65 years could expect to live nearly 12 more years; while today, a 65-year-
old person can expect to live more than 17 additional years (1).   
Prolonging life, though, has not come without consequences.  With increased 
longevity, chronic illnesses among older patients have become more prevalent and are 
now a major cause of death and disability in old age.  In this light, the Council on Ethical 
and Judicial Affairs for the AMA has suggested that the increased attention being given 
to prolonging life may eventually result in insufficient attention to protecting the quality 
of life (2).  This concern may be particularly relevant for older patients, who often report 
declining levels of quality of life with advancing age (3).  In honoring the ideals 
articulated by William Mayo, future research should investigate how medicine can 
continue to foster an individual’s quality of life as they age, particularly as they face the 




I.  Study Question 
The literature shows that on average older persons report lower scores on various 
measures of quality of life compared with their younger counterparts (3).  Quality of life 
(QOL), as a health outcome, can be most broadly defined as a multidimensional concept 
that refers to an individual’s overall life satisfaction and total well-being (4).  More 
specifically, the Center for Health Promotion at the University of Toronto has divided the 
QOL outcome into three broad domains:  well-being (including physical, psychological, 
and spiritual components), belonging (including physical, social, and community 
components), and becoming (including growth, practical, and leisure components) (5).  It 
is thought that these domains encompass the most important contributors to human well-
being.  Across these three domains, older persons on average report lower levels of 
satisfaction, resulting in reduced QOL scores.       
Demonstrating this trend in QOL scores with age, a study conducted by Farquhar 
showed that the percentage of patients who report their quality of life as “very positive” 
decreased from 52 percent of those aged 65-85 to 37 percent of those aged over 85.  
Likewise, the percentage of patients who report their quality of life as “very negative” 
increased from six percent of those aged 65-85 to 25 percent of those aged over 85 (3).  
This decline in QOL with age may be driven by changes in any or all of the domains 
mentioned in the previous paragraph, and each of these potential determinants should 
eventually be explored in an endeavor to improve QOL.  However, this particular study 
will focus solely on the role that physiologic determinants may have in declining QOL 
scores, as this is one important set of determinants which has been shown to be 
significantly affected by age.  Multiple studies have demonstrated an increase in both 
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medical morbidity and medication use with age; thus, our study will investigate any 
associations that may exist between these two variables and QOL measures. 
The older population in the United States suffers from a significantly greater 
number of medical morbidities than their younger counterparts.  For example, a study 
conducted by Stephen Machlin for the Agency of Healthcare Research and Quality 
showed that the proportion of adults with at least one chronic condition increased 
dramatically with age, ranging from 36.4 percent of young adults age 18–34 to 91.5 
percent of the elderly age 65 and over (6).  Similarly, the proportion of persons with two 
or more chronic conditions also rose dramatically with age, ranging from only 14.4 
percent of persons age 18–34 to 76.6 percent of the elderly age 65 and over.  The results 
of this study demonstrate the physiologic deterioration that often accompanies the natural 
aging process.     
As older patients suffer on average from a greater number of medical morbidities, 
they consequently utilize the health care system with greater frequency as well.  For 
example, in 2006, those aged 65 years and older made up 38 percent of all hospital 
discharges and used 43 percent of the days of care in the inpatient setting (7).  This age 
group also consumed over 30 percent of all prescription medications taken annually in 
1997 (8).  As a result of increased utilization and consumption, per person health care 
spending for the 65 and older population was $14,797 in 2004, which was 5.6 times 
higher than spending per child ($2,650 in 2004) and 3.3 times spending per working-age 
person ($4,511 in 2004) (7).  
Given the significantly greater burden of both disease and treatment endured by 
older patients, it is important to quantify and monitor the overall effect that these medical 
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morbidities and medical treatments have on patient QOL.  For example, it is quite 
possible that worsening QOL with age occurs simply as a result of age-related 
physiologic deterioration and the increased rates of chronic illness incurred by this 
population; however, as medical treatment itself can be associated with numerous side 
effects and complications, medical treatments may also be contributing to worsening 
levels of QOL in older patients.   
The impact that medical treatment has on QOL should ideally be considered for 
all forms of patient therapy; however, we think that this consideration is particularly 
relevant regarding the use of pharmacotherapy in older persons, as pharmacotherapy is by 
far the most commonly used form of medical therapy in the United States (9).  For 
example, Field et al. reported that 90% of patients aged 65 and older use at least one 
medication per week; more than 40% use five or more different medications per week, 
and 12% use 10 or more different medications (10).  Given the widespread use of 
medication among senior patients, we chose to limit our study of medication treatment to 
the use of medication and its impact on QOL measures.     
Previous attempts by investigators and clinicians to assess the impact that medical 
morbidity and medication use have on patients’ lives have taken a number of forms, 
including measurement of Adverse Drug Reactions (ADRs), Health-Related Quality of 
Life (HRQOL), and Symptom Burden.  Though each of these measures is fraught with its 
own limitations, each represents a valuable tool in assessing changes in the patient 
experience associated with changes in medication regimens and disease progression.  
These measures have allowed investigators and clinicians to quantify patient well-being.  
The next three sections will discuss the strengths and limitations of each of these 
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measures and will highlight the most important data collected to date regarding 
medication use and medical morbidity using each of them.   
 
II.  Adverse Drug Reaction (ADR) 
Definition:   
As physicians and pharmacists have become increasingly cognizant of the side 
effects associated with medical treatment, efforts have been made to quantify the 
negative impact that medication use may have on patient well-being.  Recently, the 
clinical recording of ADRs has been used to directly measure the injurious effects of 
medication use.   
The World Health Organization defines an ADR as “a response to a drug which is 
noxious and unintended and which occurs at doses normally used for prophylaxis, 
diagnosis, or therapy of disease or for the modification of physiologic function (11).”  
ADRs have been most commonly documented by pharmaceutical companies in clinical 
drug trials, by hospitals in quality improvement projects, and by research investigators in 
clinical studies.       
Findings: 
  One of the most significant findings identified regarding ADRs is their direct 
correlation with age.  A meta-analysis of 68 observational studies reported that the 
proportion of admissions related to ADRs in older people was nearly four times higher 
than that in younger people (12).  Specfically, a study conducted by Hurwitz showed that 
among patients aged over 60, 15.4 percent suffered an ADR compared with 6.3 percent 
of those aged under 60 (13).  A similar study by Seidl et al. reported that 24 percent of 
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patients aged 81 or over suffered an ADR, compared to 16 percent of patients aged 50 or 
older and 11 percent of patients younger than 50 (14).  These findings suggest that the 
risks associated with medication use increase as patients grow older. 
  Because virtually all medications have the potential to cause side effects and 
because older people consume a greater number of medications, the direct association 
between age and ADRs is not particularly surprising; however, the relationship between 
age and ADRs does not seem to solely depend upon the number of medications patients 
consume.  Rather, the association between age and ADRs is speculated to be 
multifactorial in origin with other important contributors being age-related changes in 
pharmacokinetics/pharmacodynamics and the number of medical morbidities.  A precise 
model for the interaction of these multiple factors in causing ADRs has not been 
established; however, there is data supporting the independent role of each, which will be 
discussed below.   
The number of prescribed medications taken by a patient has emerged as an 
independent risk factor for ADRs in the older population.  This is a clinically reasonable 
finding as there is increased opportunity for medication side-effects and drug-drug 
interactions when multiple medications are used.  For example, Hutchinson et al. 
conducted a study of 1026 patients which suggested a direct correlation between 
increasing age and ADRs; however, when the study controlled for the number of 
prescribed medications, the association between age and ADRs was lost (15).  In another 
study, Ghandi et al. showed that the addition of each new drug to a treatment regimen 
increased the risk of an ADR by 10% (16).  Finally, a study by Agostini et al. 
demonstrated a linear relationship between number of prescribed medications and the 
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occurrence of two commonly reported ADRs, weight loss and impaired balance.  This 
correlation persisted even after extensive adjustment for chronic medical illness (17).   
In addition to a greater sheer number of medications taken by older patients, this 
patient population also demonstrates well-documented changes in drug clearance and 
drug sensitivity that occur as a result of the normal aging process.  The four traditional 
components of pharmacokinetics are absorption, distribution, metabolism, and excretion.  
All components, except absorption, are significantly affected by age (18).  For instance, 
distribution is affected by changes in body composition, as an age-related increase in 
body fat results in a greater volume of distribution for lipid soluble medications (19).  
Additionally, metabolism of drugs by the liver (20) and excretion of byproducts by the 
kidneys are often impaired in older patients (21).  Coupled together, these physiologic 
changes prolong elimination half-life and necessitate alterations in medication dosing for 
elderly patients.  
Finally, the number of medical morbidities suffered by a patient has also emerged 
as a potential risk factor for ADRs.  As there is no clear definition of comorbidity or 
multimorbidity, the phrase ‘medical morbidity’ is used in this study to represent equally 
significant chronic conditions, rather than secondary diseases to a primary disease under 
examination (22).  The association between medical morbidity and ADRs may exist 
because an increased number of medical morbidities increases vulnerability to ADRs by 
impairing body systems; for example, cardiovascular, pulmonary, renal, and hepatic 
insufficiencies can all cause changes in pharmacokinetics and pharmacodynamics, as was 
discussed above.   
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 A study conducted by Zhang et al. demonstrated that the presence of medical 
morbidities, including congestive heart failure (CHF), diabetes, peripheral vascular 
disease, chronic obstructive pulmonary disease (COPD), and rheumatologic disease were 
all strong predictors of hospital readmissions for ADRs (12).  Similarly, a number of 
studies have also considered the effect that medical morbidities has on the occurrence of 
adverse drug events (ADEs) such as falls and incontinence; ADEs can be thought of as 
the immediate sequelae of ADRs.  For example, a study by Field et al. also showed that 
scores of five or higher on the Charlson Comorbidity Index were associated with 
increased risk of ADEs (10).  All of the above studies suggest that medical morbidities 
may have an independent and dose-related effect on the occurrence of ADRs and ADEs 
in older patients.  However, the association between morbidity and ADRs might also be 
explained by Berkson’s bias—that is, that ADRs are more likely to be identified and 
diagnosed in this population because the presence of medical morbidities increases a 
person’s contact with the health care system (12). 
Limitations:   
In summary, the occurrence of ADRs has been shown to be directly associated 
with age, medication use, and medical morbidities.  However, while the occurrence of 
ADRs provides important information regarding the risks of medication use in older 
patients, there are significant limitations associated with estimating the ill-effects of 
medication use by simply measuring the frequency of ADRs.  First, the vast majority of 
studies regarding ADRs in older patients have been conducted in the inpatient setting 
(23).  The inpatient setting is a highly-regulated environment where health care workers 
determine when a patient begins, takes, and discontinues a specific medication.  Health 
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care workers are also skilled at monitoring for and identifying ADRs, and hospitalized 
patients have repeated access to health care workers and ample opportunity to report 
symptoms.  Identification of ADRs is much more challenging in the outpatient setting 
where a significant proportion of ADRs are suffered.  In order for an ADR to be recorded 
in the outpatient setting, a patient needs to recognize a symptom, become bothered by 
that symptom, and choose to call their physician or go to the emergency department.   
The challenge of identifying ADRs in the outpatient setting has been highlighted 
in multiple independent studies.  In a study of ambulatory patients, Weingart et al. 
reported that outpatients discussed 196 (69 percent) of their 286 medication symptoms 
with their doctors.  Twenty-three percent of these patients’ unreported medication 
symptoms led to preventable or ameliorable ADRs, and one in five unreported symptoms 
resulted in an ADR that could have been prevented with medical assistance (24).  Patients 
likely failed to report nearly one-third of their symptoms for multiple reasons.  Many 
patients do not report ADRs because they do not recognize the events as drug reactions 
but rather attribute them to a disease process.  It is also possible that mild or transient 
symptoms were not reported or that patients were uncomfortable discussing potentially 
embarrassing symptoms, such as diarrhea and impotence, with their physicians (25).   
Second, in addition to difficulties in recording ADRs, using ADRs as a 
benchmark of patient well-being is also limited in that most records of ADRs do not take 
into account the severity of the medication reaction, which may be anywhere from mildly 
to severely bothersome (26).  Third, ADRs are limited in that they only reflect a small 
portion of the overall patient experience.  Record of the occurrence of ADRs does not 
instruct in any way how these reactions affect the patient experience.  For example, while 
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physiologic measures may provide important information to clinicians, they are often of 
limited interest to patients; physiologic measures often correlate poorly with functional 
capacity and well-being, the areas in which patients are most interested and familiar (27).  
The severity of an ADR and the overall affect of the medication on well-being are of vital 
importance in determining whether to continue or stop a medication.       
 
III.  Health-Related Quality of Life (HRQOL) 
Definition: 
Limitations in measuring the occurrence of ADRs in the ambulatory setting and 
their narrow reflection of the overall patient experience have led investigators to look for 
better ways to comprehensively estimate the effects of medication use and other 
physiologic determinants on patients’ lives.  The QOL outcome measure, as defined 
previously, is considered to be the most comprehensive and inclusive measure of the 
patient experience (4); however, from a medical perspective, some of the most important 
contributors to QOL are health and ability to function.  These physical aspects of QOL 
are encompassed in a more focused health outcome, namely health-related quality of life 
(HRQOL).  HRQOL has become an increasingly important measure in assessing the 
impact of disease and treatment on individuals.   
In public health and in medicine, HRQOL refers to a person’s or group’s 
perceived physical and mental health over time (28).  It is a multidimensional construct 
composed of at least four dimensions including physical function, psychological function, 
social role function, and disease or treatment symptoms (29).  HRQOL assessments offer 
a broad view of health that is consistent with the World Health Organization’s 
15 
 
conceptualization of health as a state of physical, mental, and social well-being, not 
merely the absence of disease and infirmity (30).      
HRQOL has been used across multiple disciplines to assess patient function and 
well-being.  For example, physicians have used HRQOL to measure the effects that 
chronic illness has on a person’s day-to-day life.  Similarly, public health professionals 
have used HRQOL to measure the effects of short- and long-term disabilities in different 
populations (28).  HRQOL has also been cited in the cancer literature as a way of 
describing the effect of both disease and treatment on patient well-being (31).  
Findings: 
 HRQOL has been investigated with respect to age, medical morbidity, and 
medication use.  Similarly to scores of overall QOL, HRQOL scores have also been 
shown to decline with increasing age.  A study by Sato et al. demonstrated that 
satisfaction with health and physical factors declines in the seventh decade of life, while 
satisfaction with mental and social factors declines in the eighth decade (32).  Similarly 
to the case with ADRs, the reason behind the association between age and decreased 
HRQOL is not entirely clear.   
A number of studies have examined the association between medication use and 
HRQOL, but the findings reported in the studies are inconsistent.  A study conducted by 
Henderson et al. suggests that the degree of polypharmacy is inversely related to the 
physical component of QOL scores (33).  While the physical component of QOL scores 
is not precisely equivalent to HRQOL scores, both measures aim to capture the 
physiologic determinants of QOL.  The reported association between physical QOL 
scores and medication use remained significant even after controlling for age, sex, and 
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chronic disease score.  Studies by Williams and Fitzpatrick have also reported that the 
use of multiple prescription medications can have detrimental effects on HRQOL in the 
elderly (34, 35).   
Other studies have reported no significant association between medication use and 
HRQOL.  For example, a recent study of older patients living in rural areas showed that 
the majority of participants (89 percent) felt that their ability to participate in daily 
activities was improved by their medications, and only about one-quarter of participants 
felt that their ability to participate in daily activities was limited by their medications 
(36).  In addition to this qualitative measure, this study also used one-way ANOVAs to 
compare HRQOL scores among participants who reported using none (0), few (1-2), or 
multiple (3 or more) prescription medications. There were no significant differences in 
the physical or mental components of HRQOL scores among study participants in these 
medication use groups.  However, it is important to note that the participants in this study 
used fewer medications than the national mean for seniors or threshold values used in 
previous studies (33, 37).  Taken together, the findings of these studies suggest that there 
may be a threshold value for medication use beyond which medication use confers a 
negative effect on HRQOL.   
The literature has also demonstrated a relationship between HRQOL and medical 
morbidity.  A meta-analysis conducted by Fortin et al. considered seven studies, five of 
which demonstrated an inverse relationship between number of medical morbidities and 
HRQOL (38).  All seven of the studies in the meta-analysis demonstrated that the 
physical function and symptom components of HRQOL scores were worse in patients 
with a greater number of medical morbidities; however, two of the studies in the analysis 
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disagreed with regard to overall HRQOL scores, which also included psychological and 
social role components.  These findings suggest that the decline in HRQOL scores with 
increasing medical morbidity may be driven by decreases in scores for the physical 
component of the measure.  Another study conducted by Verbrugge et al. further 
demonstrated an exponential relationship between number of morbidity and HRQOL 
scores, showing that the presence of multiple chronic conditions negatively influenced 
health status beyond the sum of the effects of each single condition (39).   
Limitations: 
In summary, HRQOL has been shown to be directly associated with age and 
inconsistently associated with medication use; furthermore, the physical component of 
HRQOL has been shown to be directly associated with number of medical morbidities.  
However, there are limitations associated with using HRQOL as a health outcome.  First, 
HRQOL can be difficult and cumbersome to measure, because by definition it requires an 
account of physical, psychological, and social components of the patient experience.  
Often patient surveys targeted at measuring HRQOL consist of numerous questions and 
may not be practical to use in a busy clinical setting.      
 Second, because HRQOL includes so many aspects of patient experience, it has 
also been criticized by some individuals for being relatively insensitive to specific 
changes in clinical condition.  For example, a randomized study compared patients with 
low-grade cerebral glioma who received high-dose versus low-dose radiotherapy (40).  
The results showed that there was no difference in HRQOL scores (based on a 47-
question survey), but patients in the high-dose treatment arm reported significantly higher 
rates of fatigue/malaise and insomnia following treatment.  In other words, even though 
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patients in the high-dose group reported a greater number of and more severe symptoms, 
this difference was not reflected in their reported HRQOL scores.  This lack of 
association may have occurred because improvements in the psychological or social 
components of the HRQOL score (eg. due to improved outlook or perspective following 
the initiation of treatment) balanced any worsening in the symptom component of the 
HRQOL score.  The lack of association may also have occurred because patients were 
able to recognize treatment-related symptoms as temporary conditions, and thus, they did 
not significantly impact HRQOL.    
The comprehensive nature of HRQOL is both one of its strengths and its 
difficulties as an outcome measure.  Given the difficulty of measuring and estimating 
HRQOL both on the part of patients and physicians, patient-reported symptom burden 
has emerged as a more attainable and practical assessment of a patient’s health-related 
experience.  Though this measure excludes the psychological and social role components 
of the HRQOL measure, symptom burden has been shown to be well correlated with 
HRQOL, and symptom severity has been demonstrated as a strong predictor of HRQOL 
scores (41).  Symptom burden is not a new concept in the literature on disease and 
treatment, but recent developments in our understanding of how to measure symptoms 
and their impact make it possible to cast symptom burden as a reasonable summary 




IV.  Symptom Burden 
Definition: 
Symptoms are inherent to the human experience, and as such, they have been 
extensively documented since the beginning of the written record.  The Ebers and Edwin 
Smith Papyri from the ancient Egyptian civilization dating back to 2600 BCE provide 
some of the earliest and most expansive accounts of symptoms, including “excessive 
urine production” and “rib pain” (29). Today, symptoms continue to be the impetus for 
nearly half of all ambulatory care office visits (42).  Symptoms play a paramount role in a 
patient’s experience of his/her disease. 
A symptom is defined by Merriam Webster as “something that indicates the 
presence of bodily disorder; subjective evidence of disease or physical disturbance” (43).  
“The presence of bodily disorder” has traditionally referred to the presence of disease or 
acute injury; however, as medicine has evolved and the treatment of disease has become 
increasingly widespread, symptoms must now be thought of as markers of the presence of 
the adverse effects of treatment as well (29).  “Subjective evidence of disease or physical 
disturbance” explicates that symptoms are the patient’s subjective perception of disease 
manifestation, and thus, they may only be known through patient report (31).  In this 
way, symptoms differ from signs of disease, such as hypertension and pulmonary edema, 
which can be objectively measured or observed by the physician.     
A symptom can be further conceptualized as multidimensional in nature with 
components that include frequency, severity, and distress (29).  The resultant effect of 
these dimensions across all symptoms experienced by the patient can be referred to as 
symptom burden.  Symptom burden is an entity which encompasses both the severity of 
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the symptoms and the patient’s perception of the impact of all his/her symptoms.  
Symptom burden is at the heart of the patient experience, and has long been used as a 
marker of well-being for patients with cancer and other terminal diseases.  Symptom 
burden contributes directly to the physical component of HRQOL and QOL scores.    
Findings: 
Much of the research on symptom burden has been limited to cancer patients.  For 
example, a number of studies have considered how additional medical morbidities impact 
symptom burden in cancer survivors.  A study conducted by Mao et al. demonstrated an 
interaction between cancer status and other medical morbidities that resulted in increased 
symptom burden (44).  In this study, cancer survivors with more than three additional 
medical morbidities reported levels of pain, psychological distress, insomnia, and overall 
symptom burden three times higher than that of cancer survivors with only one additional 
medical morbidity.  Yancik et al. has also shown the number of medical morbidities to be 
an independent predictor of morbidity and disability among elderly breast cancer 
survivors even after controlling for age and cancer stage (45). 
In addition to cancer patients, symptom burden has been less extensively explored 
in patients with chronic medical conditions.  Similarly to the treatment of terminal cancer 
patients, the goal of clinical care for advanced chronic diseases is often to slow disease 
progression and alleviate disease-associated symptoms (42).  In a study surveying 
community-dwelling older persons with chronic disease, Walke et al. showed that most 
patients with advanced COPD, cancer, or CHF experienced multiple moderate or severe 
symptoms; eighty-six percent of participants reported at least one moderate or severe 
symptom (46).  In that study, percentages of patients reporting symptoms such as pain, 
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dyspnea, anxiety, feelings of depression, and nausea were similar to that reported for 
hospitalized patients with terminal disease.  This finding implies that ambulatory patients 
with chronic diseases experience levels of symptom burden that are higher than the 
general population and comparable to hospitalized patients.    
Finally, the cancer literature has taken the study of symptom burden one step 
further, and has applied measures of symptom burden to direct patient management.  
While many cancer-related symptoms are the result of disease, it has been increasingly 
recognized that neuropathy, fatigue, sleep disturbance, cognitive dysfunction, and 
affective symptoms can also be caused by cancer treatment (31).  Symptom burden is 
being used clinically to assess the effect and impact of treatment modalities, including 
chemotherapy and radiation, in the amelioration of symptoms in palliative care.  For 
example, following a short period of treatment, patients are comprehensively reassessed 
for new, worsening, or improving symptoms, and changes in overall symptom burden are 
calculated.  Changes in level of symptom burden can then be used to instruct subsequent 
decisions regarding the continuation or termination of treatment.        
Limitations: 
While symptoms research has been collected and applied in a clinically useful 
manner for cancer patients, symptom burden in other patient populations has not been as 
extensively studied.  Furthermore, symptom burden has not been examined as it relates to 
other factors, such as number of prescribed medications, age, and other socioeconomic 
markers.  
Another limitation of symptom burden as a marker of the overall health 
experience is that it reflects only a small part of a patient’s experience (ie. the physical 
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component) with illness.  Symptom burden scores do not take into account important 
changes in psychological well-being, future outlook, financial status, and various other 
factors that may also be affected by the diagnosis of a new medical morbidity or the 
decision to begin a new treatment (29).  These factors may contribute in important ways 
to a patient’s quality of life, and they should also be addressed and optimized.  However, 
these issues may be resolved outside of the decision to start or stop medical treatment, ie. 
through social/financial consultation and intervention, etc.     
Though it is not an all-inclusive measure of HRQOL, symptom burden arguably 
captures the most important aspect of the patient experience from the perspective of 
assessing the outcomes of disease and treatment.  Because medical treatments and disease 
processes are most directly manifested as alterations in physiologic systems, these 
alternations most purely present themselves as changes in symptoms.  Consequently, 
symptom burden is a targeted measure of changes in HRQOL associated with disease and 
its treatment.  
 
V.  Summary of Introduction 
In an attempt to improve overall QOL for older patients, it is important first to 
identify the factors that may be associated with an age-related decline in well-being.  
While decreasing QOL scores with age may be driven by changes in any of the domains 
affecting QOL, we have chosen to focus on the role of potential physiologic 
determinants.  As older patients simultaneously suffer a greater number of medical 
morbidities and receive more health care services, both disease and treatment are two 
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physiologic determinants which might be associated with the age-related decline in QOL 
scores discussed earlier.   
In the literature to date, both ADRs and HRQOL have been used in various ways 
to assess changes in patient well-being associated with disease and treatment.  However, 
while both of these measures have been shown to be correlated with age, medication use, 
and medical morbidity, these measures possess significant limitations in their ability to 
instruct the clinical management of patients.  For example, while ADRs effectively mark 
the occurrence of medication side-effects, they do not indicate whether or to what extent 
the patient was disturbed by this reaction.  Therefore, if the goal of clinical care is to 
maximize patient well-being, then following the occurrence of ADRs may not be the 
most effective way to monitor clinical progress.  Likewise, HRQOL has also been used to 
monitor progress with respect to disease state and treatment.  However, because HRQOL 
theoretically captures multiple aspects of the health-related experience, it can be 
challenging to discern precisely which aspect is most affecting changes in HRQOL 
scores.  This can make it difficult to identify whether a disease or treatment itself has 
specifically improved or worsened a patient’s physical well-being.       
  From the perspective of measuring physical well-being, symptom burden is a 
more practical and targeted measure of the patient experience than HRQOL.  For these 
reasons, we have chosen to use symptom burden to assess the impact of disease and 
treatment on patient well-being in this study.  As previously demonstrated by oncologists, 
symptom burden can be used as a powerful estimate of the benefit and detriment 
associated with medical treatment options.  To this end, it is a potential tool to be used by 
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geriatricians, for whom maximizing physical well-being is one of the primary goals of 




   
Aim of this Study 
The overall objective of this study was to determine whether patient well-being, 
as estimated by self-reported symptom burden, is associated with medical treatment (eg. 
medication use) and illness (eg. medical morbidities).  Specifically, we sought to achieve 
this aim by independently assessing 1) the association between medication use and 
symptom burden and 2) the association between medical morbidities and symptom burden 
in older patients.  It was hypothesized that symptom burden would increase as the 





I.  Participants   
Participants in the study were community-dwelling older adults who were 
enrolled in the primary care clinic of the VA Connecticut Healthcare System, West 
Haven Campus.  Participants were not residents of a nursing home or other extended-care 
facility during the time of data collection.  The inclusion criteria for the study required 
that participants be aged 65 and older, able to provide consent in English, and without the 
need of a surrogate for completion of the interview.  In total, 166 participants met 
inclusion criteria.  Because only seven of the 166 respondents were female, the decision 
was made to exclude female patients from the study, as the study was unlikely to have the 
power to yield statistically significant information regarding gender.  The final research 
cohort included 159 male participants.  All participants provided informed consent.     
 
II.  Data Collection   
The current study is a secondary data analysis of primary data collected between 
August and December 2007 under the direction of Dr. Joseph Agostini.  Original data 
collection was designed to broadly assess trends in medication use, medical morbidities, 
and symptom occurrence. 
Primary Collection:   
Primary data was collected through one-on-one patient interviews conducted in 
the clinical office setting and through review of electronic medical records.  Patients were 
queried by trained research assistants regarding their age, race, sex, and education level.  
A Folstein Mini-Mental Status Exam (MMSE) was performed on all patients to assess 
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mental status; MMSE scores are based on a 30-point scale, where 30 is a perfect score.  
Information regarding prescribed medications was obtained from the medication list in 
the VA electronic medical record.  Vitamins/supplements were included in the data, but 
topical ointments were excluded.   
Medical morbidities for participants were also assessed through electronic chart 
review of patient problem lists.  Research assistants recorded 19 Charlson comorbidities 
and three non-Charlson comorbidities for participants in this study, namely hypertension, 
diabetes mellitus, arthritis, myocardial infarction, peripheral vascular disease, chronic 
obstructive pulmonary disease (COPD), cancer, congestive heart failure (CHF), 
depression, stroke, diabetes with organ dysfunction, dementia, peptic ulcer disease, liver 
disease, renal disease, lymphoma, leukemia, cirrhosis, metastatic malignancy, 
hemiplegia, tumor (solid), and AIDS.   
Symptom occurrence was evaluated through both a patient-directed questionnaire 
and electronic chart review.  Participants were asked if they regularly experienced 18 
symptoms, specifically problems with sleep, changes in mood, depression, nausea, 
diarrhea, constipation, decreased appetite, dizziness, problems with balance, headache, 
fatigue, confusion, muscular aches, rash, falls, weight loss, difficulty controlling 
urination, and difficulty thinking.  Patients in the study reported the occurrence of 771 
symptoms in total at any level of severity.  For all symptoms experienced regularly, 
participants were then asked to rate how bothersome they found the symptom to be on a 
Likert scale from zero to four, where zero was not bothersome at all and four was 
severely bothersome.  For the purposes of description, we have explicitly assigned a 
descriptor of severity to each number on the Likert scale as follows, 0 = none, 1 = mild, 2 
28 
 
= moderate, 3 = severe, 4 = very severe.  A review of patient charts, including outpatient 
clinic notes, Emergency Department notes, discharge summaries, and telephone notes, 
was conducted to assess for any additional symptom documentation by health care 
providers.  
Data Used in Current Project: 
For the purposes of data analysis for the current project, the following inclusions 
and modifications were made to the original data.  All medications documented in the 
primary data set were included in this study.  Multiple medications belonging to a single 
medication class were counted independently (e.g. if a patient was prescribed two forms 
of insulin, these would be counted as two medications).  All recorded medical morbidities 
were also included in this data analysis.   
Classification of symptom data was modified for this study.  Some symptoms 
were excluded and others were combined into symptom groups on the basis of clinical 
reasoning, literature review, and unclear phrasing of symptoms.  Three symptoms were 
excluded from the analysis because strictly defined they were not symptoms, but rather 
objective clinical signs; these symptoms included urinary incontinence, falls, and weight 
loss.  Symptoms further excluded from the study due to low rates of patient reporting 
were rash, headache, and diarrhea; exclusion of these rarely reported symptoms 
discounted 9.9 percent of total reported symptoms.   
Other symptoms were combined into related symptom groups.  Decreased mood 
and depression were combined into a single symptom group because 1) it was unclear 
clinically that patients would appreciate a difference between these entities and 2) there 
was a high rate of overlap in positive patient response to these symptoms.  Difficulty 
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thinking and confusion were combined into a single group because it was not clear 
clinically how these symptoms would be distinguished.  Likewise, dizziness and 
difficulty with balance were combined based on similar clinical reasoning. Finally, 
nausea and loss of appetite were pooled because these symptoms are clinical corollaries, 
and there is precedent for combining these entities in the cancer literature (31).  The final 
analysis included eight symptoms/symptom groups, including mood/depression, 
thinking/confusion, dizziness/balance, nausea/appetite, fatigue, constipation, muscle 
aches, and problems with sleep.   
To obtain a measure of symptom burden for each participant, we created a 
composite variable indicating the total number of severe or very severe (three or four on 
the Likert scale) symptoms experienced across the eight symptom groups.  Based on 
clinical judgment, we opted to consider symptoms with a bothersome rating >2 to be 
clinically significant.  This distinction was used because it was thought that patients who 
were severely or very severely bothered by their symptoms would be willing to modify 
their medication regimens as a result of their symptoms.  Thus, the findings of this study 
are more likely to mirror true clinical decision making.  Each significant symptom added 
one point to the symptom burden, regardless of whether the symptom was rated as severe 
or very severe.  This measure will provide a conservative estimate for symptom burden.     
 
III.  Data Analysis  
Data analysis was conducted with SAS version 9.1 (Cary, North Carolina).  
Baseline characteristics for the study populations were presented with descriptive 
statistics.  To answer the study questions, we used logistic regression analysis to assess 
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the bivariate association between Symptom Burden and Medication Number and between 
Symptom Burden and Medical Morbidity Number.  We then used multivariate analysis to 
assess the concurrent associations between Symptom Burden, Medication Number, and 
Medical Morbidity Number.   
 
IV.  Ethical Issues   
Written informed consent was obtained from the subjects or their relatives.  The 






I.  Descriptive Results 
Demographic Information:   
Table 1 shows the descriptive statistics with reliability estimates for the 
participants in this study.  This study included 159 men who presented to an ambulatory 
clinic in the VA Connecticut Health Care System.  Participants varied in age from 65 to 
90 years, and the mean age was 75.7 years.  The study population was predominantly 
Caucasian (90.6 percent), though African American patients (8.2 percent) were also 
represented at a rate similar to the general population in the state of Connecticut.  The 
frequency of Hispanic patients (1.3 percent) was significantly lower than the frequency in 
the state of Connecticut population at large (12.0 percent).  The mean education level for 
participants in this study was 11.9 years.  The mean result of Folstein Mini-Mental Status 
Exam for participants was 26.8, which is comparable to MMSE scores reported in other 
studies of older non-demented adults.        
Medical Morbidities:   
Table 1 shows the frequency of medical morbidities amongst study participants.  
Respondents were queried and their medical records were reviewed regarding the 
presence of 22 medical morbidities.  The most commonly reported medical morbidities 
were hypertension (73.6 percent), diabetes mellitus (39.6 percent), arthritis (30.8 
percent), myocardial infarction (19.5 percent), peripheral vascular disease (17.6 percent), 
cancer (16.4 percent), and COPD (16.4 percent).  All other medical morbidities were 




Medications:   
 The following classes of medications were prescribed to patients in this study:  
anti-histamines, anti-neoplastic agents, parasympatholytic and sympatholytic drugs, 
skeletal muscle relaxants, hematologic drugs, cardiac drugs, analgesics and NSAIDs, 
central nervous system drugs, diuretics, ophthalmic agents, gastrointestinal drugs, 
endocrinologic drugs, and smooth muscle relaxants.   
 
Table 1.  Descriptive Data for Study Participants  
 Mean SD Range 
Age (yrs) 75.7 6.2 65-90 
Education level (yrs) 11.9 2.5 6-19 
MMSE 26.8 2.8 18-30 
 Frequency  Percent  
Male Gender 159 100  
Race    
Caucasian 144 90.6  
African American 13 8.2  
Hispanic 2 1.3  
Medical Morbidity    
Hypertension 117 73.6  
Diabetes Mellitus 63 39.6  
Arthritis 49 30.8  
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Table 1 (continued).  Descriptive Data for Study Participants 
 
Myocardial Infarction 31 19.5  
Peripheral Vascular Disease 28 17.6  
COPD 26 16.4  
Cancer (all types) 26 16.4  
Congestive Heart Failure 17 10.7  
Depression 16 10.1  
Stroke 14 8.8  
DM with organ dysfunction 6 3.8  
Dementia 5 3.1  
Peptic Ulcer Disease 4 2.5  
Liver Disease 1 0.6  
Renal Disease 1 0.6  
Lymphoma 1 0.6  
Cirrhosis 1 0.6  
Cancer (metastatic) 1 0.6  
Hemiplegia 0 0.0  
Tumor (solid) 0 0.0  
Leukemia 0 0.0  
AIDS 0 0.0  
 
Symptoms:   
  Study participants were asked about the regular occurrence and severity of eight 
symptoms/symptom groups.  At any level of severity (0-4), patients reported a total of 
504 symptoms across all symptom groups, and all but one symptom (nausea/decreased 
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appetite) was reported by at least one-third of participants.  The symptom groups that 
were most commonly reported by respondents were dizziness/balance (56.6 percent of 
respondents), depressed mood/depression (47.2 percent), and fatigue (42.8 percent).  
Difficulty sleeping and muscles aches were also reported by 41.5 percent of respondents.  
Table 2 shows the frequency of symptom reporting at any severity by respondents.   
Symptom prevalence was also assessed for symptoms only at severe and very 
severe levels.  When only these more severe symptoms were included, patients reported a 
total of 119 symptoms.   At least one severe or very severe symptom was reported by 
fifty-three (33.3 percent) respondents.  The most commonly reported symptoms were 
dizziness/problems with balance (15.7 percent), muscle aches (11.9 percent), and 
difficulty sleeping (11.3 percent).  All other symptoms were reported by less than or 
equal to 10 percent of respondents.  Frequencies of symptom reporting are displayed in 




Table 2.  Frequency of Symptoms at Any Severity Level and at Severe/Very Severe 
Levels 
 Any Severity Level Severe/Very Severe 
Symptom Group Frequency Percent  Frequency Percent 
     
Dizziness/Balance 90 56.6 25 15.7 
Mood/Depression 75 47.2 16 10.1 
Fatigue 68 42.8 11 6.9 
Difficulty Sleeping 66 41.5 18 11.3 
Muscle Aches 66 41.5 19 11.9 
Thinking/Confusion 51 32.1 16 10.1 
Constipation 51 32.1 6 3.8 
Nausea/Decreased 
Appetite 37 23.3 8 5.0 
 
The results of this study further show that dizziness/balance was the most 
commonly reported symptom when all severity levels were considered and when only 
severe/very severe levels were considered.  Mood/depression and fatigue were commonly 
reported at any severity level, but these symptoms were relatively less commonly 
reported at severe/very severe levels.  In contrast, difficulty with thinking/confusion was 
a less prevalent symptom when all severity levels were considered, but a relatively higher 
percentage of patients who reported this symptom rated it as severe/very severe.  These 




Table 3.  Percent of Symptomatic Participants Reporting Their Symptom as Severe or 
Very Severe 
Symptom Group Any Severity Level Severe/Very Severe 
Percent Reporting 
Severe/Very Severe 
 Number Number Percent 
Dizziness/Balance 90 25 27.8 
Mood/Depression 75 16 21.3 
Fatigue 68 11 16.2 
Sleep 66 18 27.3 
Muscle aches 66 19 28.8 
Thinking/Confusion 51 16 31.4 
Constipation 51 6 11.8 
Nausea/Decreased 
Appetite 37 8 21.6 
Total 504 119 23.6 
 
Symptom Burden:  
Based on the results of symptom reporting, symptom burden (including only 
severe and very severe symptoms) was calculated for each patient.  Symptom burden for 
participants ranged from zero to five.  Results showed that the mean symptom burden 
was 0.63 +/- 1.06, and 66.7 percent of respondents reported a symptom burden of zero.  
Though the patients with a symptom burden equal to zero did not report any severe or 
severe symptoms, they still may have reported any number of mild or moderate 





Table 4.  Frequency of Patients Reporting a Given Level of Symptom Burden 
Symptom Burden Frequency Percent 
0 106 66.7 
1 24 15.1 
2 15 9.4 
3 11 6.9 
4 2 1.3 
5 1 0.6 
Mean, SD 0.63, 1.06  
Median 0  
 
 
II.  Inferential Results 
The first objective of this study was to identify and characterize any association 
between number of Medical Morbidities and Symptom Burden.  The total number of 
medical morbidities experienced by patients in the study varied from zero to six.  The 
mean number of medical morbidities per patient was 2.56 +/- 1.36.  To simplify our data 
analysis, we calculated the mean symptom burden for all participants reporting each 
number of medical morbidities.  We then charted the mean symptom burden versus the 
number of medical morbidities. Table 5 demonstrates the number of respondents that 
reported a given number of medical morbidities and the mean symptom burden per 




Table 5.  Frequency and Mean Symptom Burden of Patients Reporting a Given Number 
of Medical Morbidities 




0 4 2.5 0.00 0.00 
1 38 23.9 0.03 0.16 
2 40 25.2 0.50 1.04 
3 35 22.0 0.89 1.13 
4 28 17.6 0.93 1.05 
5 12 7.6 1.58 1.56 
6 2 1.3 1.50 0.71 
     
Mean, SD 2.56, 1.36    
Median 2    
 
The association between mean symptom burden and number of medical 
morbidities was examined through bivariate linear regression analysis.  As the number of 
medical morbidities increased from zero to six, symptom burden increased on average by 
0.29 for each additional morbidity ( R2 = 0.9423).  Figure 1 graphically depicts the 




Figure 1.  Mean Symptom Burden vs. Number of Medical Morbidities 
 
Mean Symptom Burden vs. Number of 
Comorbidities































The second objective of this study was to identify and characterize any 
association between Number of Medications and Symptom Burden.  The number of 
medications prescribed for patients in this study varied from one to 18. The mean number 
of medications was 7.91+/- 2.83.  All patients in the study took at least one medication.  
In this study, 96.9 percent of patients took five or more medications, and 27.7 percent of 
patients took 10 or more medications.  These figures are somewhat higher than those 
reported in previous studies for patients over 65.  For each number of prescribed 
medications, mean symptom burden was calculated for all patients taking this number of 
medications.  Table 6 shows the frequency of patients prescribed a given number of 





Table 6.  Frequency and Mean Symptom Burden of Patients Prescribed a Given Number 
of Medications 
Number of Medications Frequency Percent Mean Symptom Burden SD 
1 1 0.6 0.00 . 
3 1 0.6 0.00 0.00 
4 3 1.9 2.00 . 
5 35 22.0 0.00 0.00 
6 18 11.3 0.46 0.74 
7 24 15.1 0.44 0.86 
8 14 8.8 0.50 1.02 
9 20 12.6 0.93 1.49 
10 16 10.1 0.65 1.14 
11 10 6.3 0.56 0.96 
12 6 3.8 0.30 0.95 
13 6 3.8 1.33 1.03 
14 1 0.6 1.17 1.17 
15 2 1.3 0.00 . 
17 1 0.6 1.00 0.00 
18 1 0.6 0.00 0.00 
     
Mean, SD 7.91, 2.83    
Median 7    
 
The association between mean symptom burden and number of medications was 
examined through bivariate linear regression analysis.  As the number of prescribed 
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medications increased from one to 18, symptom burden increased by 0.1 for each 
increase in number of medications (R2 = 0.1975).    Figure 2 graphically demonstrates the 
association between number of medications and mean symptom burden.  
 
 
Figure 2. Mean Symptom Burden vs. Number of Prescribed Medications 
Mean Symptom Burden vs. Number of 
Medications































To estimate the independent effect that medication use and medical morbidities 
has on symptom burden, a multivariate regression analysis was conducted.  When the 
number of medical morbidities was controlled for as a confounder, the association 
between number of prescribed medications and symptom burden was reduced from 0.1 to 





The results of our study demonstrate a positive correlation between medical 
morbidity and symptom burden, but no correlation between medication use and symptom 
burden.   
 
I.  Medical Morbidity and Symptom Burden 
In our study, as the number of medical morbidities increased from zero to six, 
symptom burden increased by an average of 0.29 points with the addition of each 
subsequent medical morbidity.  The correlation between these two variables was best 
modeled using a linear regression (R2 = 0.94), and this association held true after we 
controlled for patient age and number of prescribed medications.  
The demonstrated correlation between medical morbidity and symptom burden is 
a clinically reasonable one.  As medical morbidities are most often associated with the 
occurrence of symptoms, it is logical that an increase in the number of medical 
morbidities would result in an increase in the level of symptom burden.  Additionally, 
patients who suffer from a greater number of medical morbidities are more likely to visit 
a higher number of medical specialists (12); it is conceivable that this increased 
interaction with health care providers offers these patients more opportunity to report 
symptoms, which would then be documented in the medical record and reflected in our 
symptom burden calculations.   
Though a direct correlation between medical morbidity and symptom burden 
seems clinically reasonable, there have been no studies in the literature to date explicitly 
examining this relationship in older patients.  However, our reported association is 
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consistent with much of what has previously been reported on the correlation between 
medical morbidity and other QOL measures.  For example, a meta-analysis conducted by 
Fortin et al. considered seven studies, five of which demonstrated an inverse relationship 
between number of medical morbidities and HRQOL (38).  Though the studies in 
Fortin’s meta-analysis focused on HRQOL as an outcome, symptom burden has been 
shown in previous studies to be an important contributor to HRQOL scores and has been 
shown to correlate strongly with these scores (41).   
Of the studies included in Fortin’s meta-analysis, all seven demonstrated 
diminished values for the physical component of HRQOL scores in patients with a 
greater number of medical morbidities; however, some of the studies in the meta-analysis 
disagreed regarding the association between overall HRQOL scores and number of 
medical morbidities (47).  Our study focused only on data (ie. symptom burden) that most 
strongly impact the physical component of HRQOL.  The direct correlation that we found 
between number of medical morbidities and symptom burden supports the works 
compiled by Fortin et al. and suggests that it is the physical component of illness that 
drives the decline in HRQOL associated with increasing medical morbidity.  This implies 
that the spiritual, intellectual, and social components of QOL measures may have a 
weaker correlation with medical morbidity.   
Previous studies have reported the conditions which most negatively impact QOL 
to be rheumatoid arthritis and back problems (48).  These reports are consistent with our 
finding that muscles aches is one of the symptoms most commonly reported as severe or 
very severe.  It is possible that compared with other medical morbidities, the relationship 
44 
 
of each of these medical conditions with pain causes these conditions to be more 
bothersome to patients.      
Our findings on medical morbidity and symptom burden also differ from some 
previously reported studies.  For example, a study by Cassileth demonstrated that 
HRQOL scores for five groups of physically ill patients (suffering from arthritis, 
diabetes, cancer, renal disease, or dermatologic disorders) did not differ significantly 
from those of the general public (49).  However, unlike our study, Cassileth’s 
investigation only compared patients with a single chronic condition to persons in the 
general public with no known chronic conditions.  Cassileth’s study did not examine the 
cumulative contribution of number of medical morbidities.  Combined with the 
conclusions drawn by Cassileth, the findings of our study suggest that there may be a 
dose-dependent relationship between medical morbidity and symptom burden.  Thus, it is 
quite possible that the occurrence of a single medical morbidity has only a minimal effect 
on symptom burden; but, as the number of medical morbidities increases, their 
cumulative effect on symptom burden becomes significant.   
Finally, a previous study conducted by Verbrugge showed that the level of 
disability incurred by patients increased exponentially with the accumulation of 
additional medical morbidities (39).  In other words, the presence of multiple chronic 
conditions increased the burden of disease and negatively influenced health status beyond 
the sum of the effects of each single condition.  While the results of our study do not 
duplicate this exponential association between medical morbidity and symptom burden, 
our results do demonstrate a linear correlation between these two variables.         
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In summary, the results of our study expand the work that others have done 
regarding the impact of medical morbidity on various measures of patient well-being.  
While QOL and HRQOL have been linked to medical morbidities in the past, our study 
further suggests that this linkage may be driven by changes in symptom burden, which 
would be reflected in the physical component of QOL and HRQOL scores.  Our study 
also suggests that the association between medical morbidity and symptom burden is 
linearly dose-related.     
 
II.  Medication Use and Symptom Burden 
The results of our study do not demonstrate a statistically significant association 
between medication use and symptom burden in older patients.  As the number of 
prescribed medications increased from one to 18, symptom burden increased by an 
average of 0.1 points for each additional medication (R2 = 0.1975).  However, after the 
number of medical morbidities was controlled for as a confounding factor in the analysis, 
symptom burden increased by an average of only 0.04 points for each additional 
medication.   
Our findings differ from those reported by previous studies in the literature, many 
of which do show an association between medication use and various measures of patient 
well-being.  While there have been no studies to date which specifically explore the 
relationship between medication use and symptom burden, a number of studies have 
investigated the association between medication use and ADRs  (33, 35, 50).  While it 
may be true that patients taking more medications suffer a greater number of ADRs, our 
study suggests that the occurrence of these adverse reactions does not significantly 
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impact symptom burden.  For instance, many patients may not be aware that they are 
experiencing ADRs, or they may only be minimally bothered by these reactions.   
There have also been studies reported in the literature that directly consider the 
association between medication use and QOL scores; however, the results of these 
studies are conflicting.  A study conducted by Henderson suggests that the degree of 
medication use is inversely related to the physical component of QOL scores (33).  
Although this study did control for six medical morbidities, it did not control for some 
important morbidities, including cardiovascular disease and renal disease.  The study was 
also limited to a population of American Indians.  In contrast, the results of a study 
conducted by Graffen demonstrated that in a rural elderly population, there was no 
demonstrated association between medication use and lower QOL scores (37). 
Our study does not investigate the reasoning behind the reported lack of 
association between medication use and symptom burden.  However, based on clinical 
reasoning, we conjecture that perhaps the benefits and detriments associated with 
medication use counterbalance one another.  It is possible that any benefit in symptom 
relief conferred by the addition of a new medication is offset by any adverse effects also 
associated with the use of this new medication, including the occurrence of ADRs.   For 
example, adding a beta blocker to a medication regimen may improve symptoms of 
angina and palpitations, but it may concurrently cause dizziness and fatigue, resulting in 




III.  Limitations and Strengths of the Study 
Our investigation has several limitations.  First, the cross-sectional design of our 
study precludes the determination of causality of the associations we observed.  While we 
have shown that medical morbidities and symptom burden are associated with one 
another, it cannot be determined whether this increase in symptom burden results directly 
from the presence of these disease states.   However, it is reasonable from a clinical 
perspective to assume that medical conditions do result in the development of symptoms 
and impact symptom burden.      
A second potential limitation of this study is recall bias.  The symptoms reported 
by patients in this study were not necessarily present at the time of the interview.  It is 
conceivable that individuals might have experienced other symptoms that they did not 
report, or conversely, that they may have forgotten to report symptoms that they did 
experience.  However, since we only included severe and very severe symptoms in our 
symptom burden calculations, it is more likely that participants’ recall of symptoms was 
accurate, as a person may be more likely to remember a more severe symptom.  One 
might also expect that severe or frequent symptoms would be more likely to be reported 
by patients to physicians and thus be recorded in the medical record.  
   A final set of limitations of this study stems from the characteristics of our 
sample population.  Because our study was restricted to community-dwelling older male 
patients, we cannot generalize our results to women, non-community dwelling patients, 
or younger patients.  Conflicting studies have reported both male and female gender as 
potential risk factors for ADRs; this study does not clarify that association.  We also do 
not report on the effects that other potential confounding variables may have on symptom 
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burden, including socio-demographic status, health habits, and social support, all of 
which have been recognized as impacting QOL in older persons (51).  Furthermore, we 
cannot be certain that our questionnaire includes all of the symptoms important to 
community-dwelling patients; at present, there is no generally accepted list of the most 
important symptoms for this population.  Finally, it is possible that this study was 
underpowered to detect an association between medication use and symptom burden. 
 
IV.  Study Implications 
It has been previously demonstrated that older patients suffer from a greater 
number of medical morbidities and receive more medical services than their younger 
counterparts.  Though many experts believe that the provision of abundant health care for 
older individuals has resulted in extended life expectancy, the literature continues to 
show that older patients report an age-related decline in QOL (3).  This trend highlights 
the management of symptom burden as an area of potential improvement in the care of 
older patients.  As was discussed earlier in this paper, it is not clear from the existing 
literature whether this decline in QOL may arise in association with increased medical 
morbidity, increased medical treatment, or both.       
The first major implication drawn from this study is based on our reported 
positive association between medical morbidity and symptom burden.  This finding 
implies that the previously reported decline in QOL associated with increasing number of 
medical morbidities may be at least partly driven by an increase in symptom burden.  
Increased symptom burden directly impacts the physical component of QOL and 
HRQOL scores.  This conclusion suggests that mitigating symptom burden should be a 
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targeted outcome for patients who designate improved QOL as one of their primary goals 
of medical care.  
In an effort to alleviate symptom burden, there are many strategies which can be 
employed by both physicians and patients.  Some potential strategies include physical 
therapy, massage therapy, pharmacotherapy, lifestyle modifications, and alternative 
medicine therapies.  Given the low adverse effect profile of most of these interventions, 
physicians may consider counseling their patients regarding these strategies in an attempt 
to reduce physical symptoms and improve QOL.  The results of our study suggest that the 
management of symptoms is a goal of care which should be considered as important as 
extending life and preventing illness.   
The second implication drawn from this study is based on the lack of association 
we reported between medication use and symptom burden.  To improve symptom burden, 
our findings imply that we may gain the most benefit from reducing medical morbidity, 
irrespective of the number of medications that patients are prescribed.  However, a 
number of reputable studies have demonstrated that a high level of polypharmacy is a risk 
factor for falls and the occurrence of other ADRs in older patients (17, 52).  In light of 
these findings, we do support limiting the use of multiple medications as much as 
possible.   
If our goal in prescribing medications to this population is to reduce symptom 
burden while still limiting polypharmacy, then one strategy for achieving these outcomes 
may be to focus on the prescription of medications intended to reduce symptom burden, 
as opposed to medications that are intended to prevent disease development/progression.  
Many medications are prescribed to extend life and prevent the development of disease, 
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but these medications may not confer major improvements in symptom reduction.  This 
may be true for some of the most commonly prescribed medications for older patients, 
including ace-inhibitors and diuretics for hypertension, anti-depressants for mild mood 
disorders, aspirin and warfarin for anti-coagulation, and statins for hypercholesterolemia.  
Though these medications bestow a benefit in long-term health outcomes and life 
expectancy, they often do not contribute to perceptible changes in symptom burden.  In 
contrast to those prevention-centered medications, some medications are targeted 
specifically at improving symptoms.  In terms of reducing symptom burden, it is 
important to continue these medications which directly improve symptoms associated 
with medical morbidities.  Analgesics are an example of an important symptom-centered 
medication.     
In addition to talking with patients regarding real-time changes in symptom 
burden and various strategies to improve symptom burden, this study also highlights the 
importance of talking with patients extensively about their goals of medical care.  In 
managing the care of older patients with multiple medical conditions, patients should be 
advised that there may be trade-offs to consider regarding improvements in life 
expectancy and quality of life.  As discussed above, some medical treatments and 
lifestyle modifications might advance one of these objectives more than the other, or even 
at the expense of the other.  Patients’ priorities on these issues will vary from person to 
person, and they may instruct physicians as to whether or not to continue a particular 
medication.  This technique has been used effectively by oncologists in patients with 
terminal disease (29). 
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V.  Future Research 
Additional studies that longitudinally examine the associations reported in this 
study would add to the existing body of knowledge.   While a number of longitudinal 
studies following the natural course of aging have been conducted, these studies have not 
explicitly investigated the association between medical treatment, medical morbidity, and 
overall symptom burden.  In a potential longitudinal study, a cohort of older patients 
could be followed throughout the natural course of aging.  Patients could be followed as 
new disease processes develop, progress, and are treated with various medical treatments.  
Throughout this time period, symptom burden could be repeatedly measured by health 
care providers at specified time intervals, and symptom burden, medication use, and 
medical morbidity burden could then be correlated over time.   
Future research could also be pursued within the confines of a cross-sectional 
analysis.  Building on the association we reported between medical morbidities and 
symptom burden, a future study might consider whether particular medications or 
medication classes drive trends in symptom burden.  For example, the addition of a beta-
blocker to a medication regimen may reduce symptom burden more or less than the 
addition of a daily aspirin.  Future research might also be done to determine which 
symptoms are associated with the greatest increase in symptom burden; these findings 
would help direct the targets for pharmacotherapy.     
Finally, to further support the conclusions and recommendations drawn from this 
study, it should be determined whether symptom-directed changes in medication 
regimens lead to a reduction in symptom burden and HRQOL over time.  This conclusion 
could be investigated by querying patients regarding symptom occurrence and severity 
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following medication changes and comparing the strength of the association between 
symptom burden and medication use in this population to that of a control group in whom 





Much time and resources have been spent in the pursuit of the ideals expressed by 
Dr. William Mayo to improve both quantity and quality of human life.  While advances 
in medicine have allowed us to make great strides in prolonging life, in regards to 
furthering the quality of life in older patients, the research suggests that there remains 
room for improvement.  An understanding of the barriers and facilitators that affect 
HRQOL throughout the life course is important for identifying those at risk for less than 
optimal quality of life and for designing appropriate health-promoting interventions. 
This study investigated the effect that medical morbidity and medication use have 
on one physiologic determinant of HRQOL, namely, symptom burden.  Of the two 
determinants considered, the presence of medical morbidity was shown to have a stronger 
negative effect on symptom burden than was medication use.  These findings suggest that 
physicians should focus more attention on the alleviation of symptoms associated with 
medical morbidities in an attempt to improve QOL for their patients.  There are many 
strategies which can be employed by both physicians and patients to reduce symptom 
burden, and physicians should encourage their patients to trial these strategies in an 
attempt to improve physical symptoms and QOL.   
In conclusion, this study has employed a patient-centered health outcome to 
measure the impact that both disease and treatment have on quality of life.  As we 
continue to strive to slow the decline in HRQOL experienced by older patients, further 
research should be done to identify and assess other factors which may also contribute to 
this decline.  Only through sustained inquiry can we identify methods through which 
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society can foster an individual’s HRQOL, particularly as that person faces the possibility 
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